#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Philippa Burns Email
Director Research & Development . Cambridge Epigenetix
How to contact Philippa Burns
Join and see Philippa's contact info for free!Current Roles
Employees:
113Revenue:
$17.5MAbout
Cambridge Epigenetix aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification. We utilise innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline. For more information, visit www.cambridge-epigenetix.com or email info@cambridge-epigenetix.com.Cambridge Epigenetix Address
The Trinity Building, Chesterford Research PaCambridge, MA
UK